The male god of magic capital

Chapter 134 135 The Private Equity Fund Family Fund is making a lot of money!

The assets of the Luo Family Foundation's A-share account reached 2.5 million, and the rate of return was as high as 66.66% in just two days, which was quite a fruitful result.

The next step is to wait for the stock price of Cape Biotech to continue to fly.

It should be no problem to triple the A-share account this time.

As for Qin Qihai, Xu Rendong said to suppress the stock price, hehe, Luo Cheng doesn't care, but wants to see how Qin Qihai suppressed the stock price, kept shorting, kept suppressing?

It is indeed possible to do this, but in the face of long-term value investors, this trick will not work at all, and Qin Qihai still needs to control this company and needs to attract money.

Luo Cheng is not worried at all about the next sharp rise in the stock price.

However, the stock price of Opcom, which is fully stocked by Chengtian Private Equity, is still fluctuating between 70 and 90 yuan per share. Huang Hanxing, Li Minqiao and others seem to deliberately suppress the stock price, but it’s okay, just hold it for a long time, and slowly follow Dah Sing Fund, East Asia Fund consumption.

The recent net value of Chengtian Public Fund has also remained stable, and the medical sector, which is heavily held, has not experienced a sharp drop.

Of course, Chengtian Public Fund also holds a large number of Opcon Vision shares, worth nearly 20 billion, and Chengtian Private Equity Fund holds valuable stocks, worth about 60 billion. Calculated, Chengtian Holdings holds a total of Opcon Vision worth 80 billion Its stock accounts for more than 10% of its market value, and it can be regarded as a major shareholder.

Of course, the holdings are scattered, and Luo Cheng will not appoint directors, because these stocks will be sold at any time.
Of course, if it is necessary, if a general meeting of shareholders is held temporarily, the 10% equity of Chengtian Holding Company can also appoint a representative to attend.

And the stock price of Chengtian Holdings Company has reached 7000 yuan a share, and its market value has reached 70 billion. Although this stock price is inflated, the stock market is so unreasonable and illogical.

Although the subsidiaries of Chengtian Holding Company are either losing money or burning money, Chengtian Private Equity Fund and Chengtian Public Equity Fund have performed well, as long as investors are optimistic about their prospects.

The Luo family foundation holds 75% of the shares of Chengtian Holdings, worth 52.5 billion.

Next, as long as the performance of Chengtian Private Equity Fund and Chengtian Public Fund continues to expand, the share price of Chengtian Holdings can reach 1 yuan a share in minutes, and the market value will also reach 100 billion.

Just think about it.

Chengtian Holding Company will soon become a large financial group, and then with Chengtian Holding Company as the core, a huge Chengtian Department will be created, which will have many listed subsidiaries.

As the financial center of the country, Shanghai's hot money is concentrated here, and the funds of rich people from all over the country will also flow here. For example, many customers of Chengtian Holding Company come from all over the country.

The accumulation of hot money gave Luo Cheng the capital to quickly create a financial group. The scale of Chengtian's private equity fund was 50 billion, while the scale of Chengtian's public equity fund exceeded 300 billion.

When a large financial group is successfully built, it will create a Chengtian group to participate in various industries.

After creating the Chengtian system in Shanghai and spreading it to all regions of the country, he will use Xiangjiang, an international financial center, as a springboard to create a global financial technology consortium.

At present, there are still 2.5 million Hong Kong dollars in the Hong Kong stock account of the Luo Family Foundation. First, some funds will be accumulated in Hong Kong stock market operations. Finally, before Cheng Tian Holdings Company becomes a large financial group, the Luo Family Foundation can control a medium-sized financial company listed in Hong Kong. , and then Chengtian Holding Company will carry out mergers and acquisitions, and Xiangjiang's financial company will merge with the domestic Chengtian Holding Company, so that Chengtian Holding Company will go abroad and face the world.

After all, the assets of Chengtian Holding Company are all in the form of RMB. If you want to transfer large-scale assets in the form of Hong Kong dollars, US dollars, euros, and Japanese yen to acquire or acquire overseas companies, you need the approval of the SAFE, which is very troublesome, unless it is Importing companies, such as importing chips, various equipment, instruments... food, etc., otherwise it would be difficult to convert large sums of RMB into US dollars for overseas acquisitions.

Of course, tens of millions of small money can be traded privately at any time, but large amounts of money cannot be traded privately. For example, if 70 billion RMB is converted into US dollars, that is 10 billion US dollars. That small foreign trade company can pay Can afford a billion dollars?
You need to apply to the SAFE for this. Basically, the approval is not approved. You are not going to buy chips, equipment, instruments, or other high-tech products, such as various high-end parts of imported motor vehicles.

Previously, Luo Cheng had a private loan transaction with She Zhengchu, a client of Chengtian Private Equity Fund. She Zhengchu’s foreign trade company was doing business between Shenzhen and Xiangjiang. After obtaining Hong Kong dollars, they needed to convert them into RMB, and then continue to use domestic production to sell their products to Xiangjiang. Get Hong Kong dollars again.

Therefore, She Zhengchu owns Hong Kong dollars in Hong Kong's bank account, and he directly lent 1170 million Hong Kong dollars to Luo Cheng, which was transferred to Luo Cheng's bank account opened at Hong Kong Citibank, and Luo Cheng lent Yu Zhengchu 1000 million yuan in China, which was transferred to Yu Zhengchu. in domestic bank accounts.

This concluded a deal, but such a deal was only a small-scale one, and She Zhengchu didn't have many Hong Kong dollars to take over hundreds of millions of RMB.

In the future, if Cheng Tian Holdings wants to go abroad, the Luo Family Foundation will need 2.5 million Hong Kong dollars in Hong Kong stocks. If the operation is good, the 2.5 million will quickly expand.

In the future, the Luo Family Foundation will acquire a 75% stake in a medium-sized listed financial company in Xiangjiang, making preparations for Chengtian Holdings to enter Xiangjiang and go international.

At that time, let Chengtian Holding Company acquire the medium-sized financial company of Xiangjiang, and then Chengtian Holding Company will be listed in the two places directly. If there is a shortage of Hong Kong dollars, what should we do with US dollars?
At that time, Chengtian Holdings, which is listed in both places, will directly issue new shares in the Hong Kong stock market for financing. This large-scale Hong Kong dollar and US dollar will come soon!
At present, the Luo Family Foundation's 2.5 million Hong Kong dollars, Luo Cheng already has a place to go, and that is Mancang Xinda Biological Company!
This Cinda Biological Company is one of the partners of Opconvision, and also a partner of China Resources Medical, Jiu'an Medical and other companies.

Behind Innovent Biotech is Huaxia Innovent, a giant asset management company.

It was rumored a long time ago that Innovent will cooperate with a Swiss pharmaceutical giant.

Now the stock price of Innovent Biological has fallen below 20 Hong Kong dollars per share, and has fallen all the way to 18 Hong Kong dollars per share in recent days.

It may still fall a little bit more, with a high probability of falling to 16 Hong Kong dollars per share, but Luo Cheng didn't wait for it to continue to fall, and directly swept the stock in large sums.

Its usual trading volume is not large, and Luo Cheng's 2.5 million Hong Kong dollars of funds entered the market, which directly raised the stock price of Innovent Biological Company.

18.25
18.78
19.77
20.14
20.99
21.55
22.00 positions!

Luo Cheng bought a total of 1250 million shares at an average price of 20.00.

Temporary floating profit of 2500 million Hong Kong dollars.

However, the floating profit soon disappeared, and the stock price of Cinda Biotech was raised by Luo Cheng for a long time, and then slowly fell again, all the way down to 20.00.

In the next two days, the stock price of Innovent Biological Co., Ltd. has been running between HK$16 and HK$22. Luo Cheng's account fluctuated between losses and profits.

By Saturday, big, good news arrives.

But it is not known whether the news is true.

Innovent will cooperate with the Swiss Roche Group, which was founded in 1896. Roche is headquartered in Basel, Switzerland. It is a world leader in the field of pharmaceuticals and diagnostics. A patient provides a targeted treatment plan, and now Roche ranks 2020th in the 2000 Forbes Global 74 list, with annual turnover
566 billion dollars!
Terrible medical giant!

And the cooperation between Innovent and Roche Group?

Large Orders?
On Sunday, Innovent Biologics announced that a wholly-owned subsidiary of the company had reached a strategic cooperation agreement with the Roche Group.

The parties will focus on research, clinical development and commercialization of multiple bispecific antibody and cell therapy products for direct treatment of hematological and solid tumors.

It is reported that the potential milestone of this cooperation between the two parties totals about 19.6 billion US dollars, which is one of the largest international technical cooperation in the field of biopharmaceuticals in China so far, and it is also the first technology platform cooperation between Roche Group and Huaxia Biopharmaceutical Enterprises.

Under the terms of the agreement, Innovent will pay an upfront payment, development and commercialization for its non-exclusive use of certain Roche technologies to discover and develop 2:1 bispecific T cell antibody (TCB) and general CAR-T platforms. Milestone payments and commissions on product sales.

Innovent will develop, manufacture and commercialize these products.

Roche Group reserves the right to repurchase the development and commercialization rights of each product outside of China.

If Roche exercises all its options, it will pay Innovent Biologics a total of US$1.4 million. If all products are successfully developed and commercialized, it will pay a total of approximately US$19.6 billion in milestone payments for product development, approval and sales. In addition, A double-digit sales commission will also be paid for each product.

This is great news.

The Hong Kong stock market opened on Monday, and the stock price of Innovent Biologics soared!
It has been sought after by international investors.

23.45
24.49
26.75
27.94
28.97
···
30.00 positions!

The Luo family foundation has a profit of 10 Hong Kong dollars per share, a floating profit of 1.25 million Hong Kong dollars, and a net account value of 3.75 million Hong Kong dollars.

On Tuesday, the stock price of Innovent Biotech continued to skyrocket!

31.55
33.44
34.77
38.45
39.40
40.00 positions!

In just two days, the stock price rushed from 20 Hong Kong dollars to 40 Hong Kong dollars.

The 1250 million shares held by the Luo Family Foundation are worth HK$5 million.

On Wednesday, the stock price continued to rise sharply, rushing all the way to the 45.00 position, but it didn't take long for it to turn around and fall to 40.00 Hong Kong dollars per share.

Obviously, it was caused by many profitable long positions.

A number of major international banks maintain a "buy" rating on Innovent.

Bank of America Merrill Lynch previously released a report saying that based on the faster-than-expected progress in product line research and development and the promotion of the PD-1 monoclonal antibody drug Tyvyt, the bank raised the target price of Innovent Biologics from HK$40 to HK$60, reiterating the "buy" " rating.

Credit Suisse also released a report earlier, raising the target price of Cinda Biological from HK$40 to HK$55.5, maintaining the "outperform" rating.

So many major international investment banks are bullish, and Luo Cheng is also relieved. From now on, he will continue to hold the stock of Innovent Bio, and hold it for a long time.

In fact, Luo Cheng is optimistic that its stock price will double again, rushing to 90 Hong Kong dollars a share, or even 100 Hong Kong dollars a share.

As a partner of Innovent Biotech, the stock price of Opconvision has also risen recently. Huang Hanxing and Li Minqiao did not continue to wash the market to suppress the stock price. The stock price of Opconvision has risen to 90 yuan per share, and it has stabilized at 90 yuan per share. above.

The Chengtian public offering fund has a full position of 50 billion yuan, and the opening position is 60 yuan per share, with a floating profit of 50%. The floating profit on the book is 25 billion yuan, which can be described as a fruitful harvest.

Chengtian Public Fund also holds shares in Opconvision,

And Qin Qihai did not deliberately suppress the stock price of Opconvision's supplier Cap Biotech, and the stock price of Cap Biotech finally rushed to 15 yuan per share.

The Luo family foundation holds 2000 million shares, and the opening position is 7.5 yuan per share. Now the floating profit is 1.5 million, and the account assets have reached 3 million.

Whether it is Chengtian Private Equity Fund or Chengtian Public Fund, the Luo Family Fund has gained a lot during this period.

Huang Hanxing and Li Minqiao called, saying that they wanted to buy the shares of Opconview owned by Chengtian Private Equity Fund.

Make an appointment with Luo Cheng at the coffee shop next to the Citi Building.

Luo Cheng asked directly: "What's the price you gave?"

"A premium will do."

Li Minqiao: "How about the market price?"

Huang Hanxing: "You hold so many shares of OPCIS, and it is difficult to ship them out. The market price we gave you is already very good, so don't be too greedy!"

Bank of East Asia and Dah Sing Bank are very optimistic about the future prospects of Opcon. It is safe for the stock price to stand above 100 yuan, and it is not a problem to stand above 150 yuan per share.

They planned to buy goods at a low price before, but Chengtian Private Equity Fund took the lead. As a result, they could only buy goods between 80 and 90 yuan per share. Recently, they have been deliberately suppressing the stock price, but there are many good news and the market is also strengthening. They I can only regret.

Luo Cheng shook his head and refused: "The two of you should give me at least 100 yuan per share. I am very optimistic that the stock price of Opconvision will rise all the way to 120 yuan per share, or even 150 yuan per share. The Chengtian Private Equity Fund is only for short-term operation, not particularly for long-term operation, if the two of you want to buy it, I will sell it to you at the price of 100 yuan per share."

Huang Hanxing: "100 yuan per share? Impossible, you were rushing to sweep goods under 60 yuan per share before, and you will earn so much in the future, so don't be too greedy."

Li Minqiao: "Mr. Luo, you must know that at that time, our East Asia Fund, Dah Sing Fund, and Taixin Mixed Fund dropped the stock price of Opconvision to below 60 yuan. At that time, retail investors and small hot money sold a lot of stocks. Lost so many stocks, you have made enough money!"

Speaking of this, the two were very angry in their hearts. At that time, they smashed the market to make retail investors, and the small hot money broke their hearts and sold a large number of stocks. They waited for the stock price to fall to 50 yuan per share. Yuan per share frantically swept up the goods, swept up all the sales, and they made a wedding dress for Luo Cheng, very annoyed and unwilling.

Luo Cheng insisted: "I still want 100 yuan per share!"

The two refused to agree, and broke up again.

(End of this chapter)